CN111065394B - 中枢神经系统病症的治疗 - Google Patents

中枢神经系统病症的治疗 Download PDF

Info

Publication number
CN111065394B
CN111065394B CN201880055307.8A CN201880055307A CN111065394B CN 111065394 B CN111065394 B CN 111065394B CN 201880055307 A CN201880055307 A CN 201880055307A CN 111065394 B CN111065394 B CN 111065394B
Authority
CN
China
Prior art keywords
use according
syndrome
day
benzyl
hydroxypiperidin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201880055307.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN111065394A (zh
Inventor
西俊哉
近藤伸一
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Priority to CN202310328785.4A priority Critical patent/CN116370475A/zh
Publication of CN111065394A publication Critical patent/CN111065394A/zh
Application granted granted Critical
Publication of CN111065394B publication Critical patent/CN111065394B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
CN201880055307.8A 2017-08-31 2018-08-30 中枢神经系统病症的治疗 Active CN111065394B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202310328785.4A CN116370475A (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762553070P 2017-08-31 2017-08-31
US62/553,070 2017-08-31
PCT/JP2018/032949 WO2019045121A1 (en) 2017-08-31 2018-08-30 TREATMENT OF CNS DISEASES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202310328785.4A Division CN116370475A (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗

Publications (2)

Publication Number Publication Date
CN111065394A CN111065394A (zh) 2020-04-24
CN111065394B true CN111065394B (zh) 2023-03-31

Family

ID=63722720

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880055307.8A Active CN111065394B (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗
CN202310328785.4A Pending CN116370475A (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202310328785.4A Pending CN116370475A (zh) 2017-08-31 2018-08-30 中枢神经系统病症的治疗

Country Status (7)

Country Link
US (4) US11285139B2 (enExample)
EP (1) EP3675852A1 (enExample)
JP (2) JP7196157B2 (enExample)
KR (1) KR102680786B1 (enExample)
CN (2) CN111065394B (enExample)
MX (1) MX2020001732A (enExample)
WO (1) WO2019045121A1 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4717314A2 (en) 2011-10-14 2026-04-01 Sage Therapeutics, LLC 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
WO2014169836A1 (en) 2013-04-17 2014-10-23 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
SMT202100509T1 (it) 2013-04-17 2021-11-12 Sage Therapeutics Inc Steroide di c21-n-pirazolile 19-nor c3,3-disostituito per l'uso in terapia
CN117304245A (zh) 2013-04-17 2023-12-29 萨奇治疗股份有限公司 刺激神经活性的19-去甲类固醇及其使用方法
US9725481B2 (en) 2013-04-17 2017-08-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
CA2918735C (en) 2013-07-19 2023-08-01 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
CN105579043B (zh) 2013-08-23 2021-09-14 萨奇治疗股份有限公司 神经活性类固醇、组合物和其用途
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
MY190408A (en) 2014-10-16 2022-04-21 Sage Therapeutics Inc Compositions and methods for treating cns disorders
US20170233433A1 (en) 2014-10-16 2017-08-17 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
LT3250210T (lt) 2015-01-26 2021-04-12 Sage Therapeutics, Inc. Kompozicijos ir būdai, skirti gydyti cns sutrikimus
DK3258939T3 (da) 2015-02-20 2022-12-12 Sage Therapeutics Inc Neuroaktive steroider, sammensætninger og anvendelser heraf
WO2018013613A1 (en) 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
CA3030420C (en) 2016-07-11 2025-11-18 Sage Therapeutics, Inc. C7, C12 AND C16 SUBSTITUTED NEUROACTIVE STEROIDS AND ASSOCIATED METHODS OF USE
TW202604538A (zh) 2016-08-23 2026-02-01 美商賽吉醫療公司 結晶19-去甲c3,3-二取代之c21-n-吡唑類固醇
CN111432812A (zh) 2017-11-14 2020-07-17 爱思开生物制药株式会社 用于预防、减轻或治疗失神发作或显示失神发作的癫痫的氨基甲酸酯化合物的用途
WO2020021372A1 (en) * 2018-07-24 2020-01-30 Zenvision Pharma Llp Nasal drug delivery system of brivaracetam or salt thereof thereof
GB2580881A (en) * 2018-11-30 2020-08-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
JP7670626B2 (ja) 2019-05-31 2025-04-30 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイド及びその組成物
CN114746408B (zh) * 2019-12-02 2025-02-14 豪夫迈·罗氏有限公司 炔基-(杂芳基)-甲酰胺hcn1抑制剂
GB2597312A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597311A (en) * 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
GB2597285A (en) 2020-07-20 2022-01-26 Gw Res Ltd Use of cannabidiol in the treatment of seizures associated with rare epilepsy syndromes related to genetic abnormalities
US20240197704A1 (en) * 2021-04-09 2024-06-20 Johns Hopkins University Treatment methods and compositions comprising perampanel
CN115487144A (zh) * 2021-06-18 2022-12-20 北京万全德众医药生物技术有限公司 一种卢非酰胺的口服液制备方法
WO2023175591A1 (en) * 2022-03-18 2023-09-21 Takeda Pharmaceutical Company Limited Methods of treating neurological diseases
WO2024100531A1 (en) * 2022-11-07 2024-05-16 Takeda Pharmaceutical Company Limited Method of treating seizure disorders
WO2025126159A1 (en) * 2023-12-15 2025-06-19 Takeda Pharmaceutical Company Limited A method for treating a neurological disease in a recreational drug user
WO2025257799A1 (en) * 2024-06-14 2025-12-18 Takeda Pharmaceutical Company Limited Methods of treating dravet syndrome
CN121550436B (zh) * 2026-01-23 2026-05-12 四川大学华西医院 组合物及联合用药方式

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8648079B2 (en) 2011-10-07 2014-02-11 Takeda Pharmaceutical Company Limited Heterocyclic compounds
EA029056B1 (ru) 2012-12-11 2018-02-28 Такеда Фармасьютикал Компани Лимитед Гетероциклическое соединение
WO2014163161A1 (ja) 2013-04-04 2014-10-09 武田薬品工業株式会社 複素環化合物
JP6807322B2 (ja) 2015-10-16 2021-01-06 武田薬品工業株式会社 複素環化合物の製造方法

Also Published As

Publication number Publication date
CN111065394A (zh) 2020-04-24
US20220168294A1 (en) 2022-06-02
CA3073925A1 (en) 2019-03-07
MX2020001732A (es) 2020-03-20
WO2019045121A1 (en) 2019-03-07
JP7196157B2 (ja) 2022-12-26
CN116370475A (zh) 2023-07-04
JP2023027267A (ja) 2023-03-01
US11285139B2 (en) 2022-03-29
JP2020532508A (ja) 2020-11-12
EP3675852A1 (en) 2020-07-08
US20250281477A1 (en) 2025-09-11
US20230087903A1 (en) 2023-03-23
KR20200046022A (ko) 2020-05-06
KR102680786B1 (ko) 2024-07-02
JP7469445B2 (ja) 2024-04-16
US20200306238A1 (en) 2020-10-01

Similar Documents

Publication Publication Date Title
JP7469445B2 (ja) Ｃｎｓ状態の治療
US20250082651A1 (en) Ganaxolone for use in treating genetic epileptic disorders
US20240245631A1 (en) Methods of treating lennox-gastaut syndrome using fenfluramine
JP6037615B2 (ja) 肝性脳症を治療する方法
JP2022521446A (ja) 発作制御を改善するための製剤
BR112020002077A2 (pt) usos combinados de lasmiditan e de um antagonista de cgrp na preparação de medicamentos para tratamento de enxaqueca e outras dores de cabeça
Ketter et al. A 6-month, multicenter, open-label evaluation of beaded, extended-release carbamazepine capsule monotherapy in bipolar disorder patients with manic or mixed episodes
EP3687518A1 (en) Use of fenfluramine formulation in reducing number and frequencies of convulsive seizures in patient populations
WO2019067413A1 (en) USE OF A FENFLURAMINE FORMULATION TO REDUCE THE NUMBER AND FREQUENCIES OF CONVULSIVE CRISES IN PATIENT POPULATIONS
CN117244056A (zh) 用于治疗阿尔茨海默病的含有抗Aβ初原纤维抗体和β-分泌酶BACE1抑制剂的组合物
JP2015505314A5 (enExample)
HK40083190A (en) Methods of treating lennox-gastaut syndrome using fenfluramine
EA052165B1 (ru) Ганаксолон для использования в лечении наследственных эпилептических заболеваний
HK1255881A1 (zh) 使用芬氟拉明治疗lennox-gastaut综合征的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant